0000950170-22-014236 | 10-Q | XBRL Viewer

Label	Element	Value
Expected Ressarch Services Period	fate_ExpectedRessarchServicesPeriod	4 years
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	$ (5,881,000)
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	8,700,000
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	(14,240,000)
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	7,956,000
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	1,200,000
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	1,100,000
Increase Decrease In Fair Value Of Stock Price Appreciation Milestones	fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	$ (14,240,000)
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	Greater than 1
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or les
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	1 or less
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	Greater than 1
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	Greater than 1
Investment Maturity Date Range	fate_InvestmentMaturityDateRange	Greater than 1
Percentage Of Common Stock Ownership Upon Preferred Stock Conversion	fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion	9.99%
Percentage Of Common Stock Ownership Upon Preferred Stock Conversion	fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion	19.99%
Percentage Of Common Stock Ownership Upon Preferred Stock Conversion	fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion	19.99%
Milestone Payments	fate_MilestonePayments	$ 10,000,000.0
Milestone Payments	fate_MilestonePayments	10,000,000.0
Milestone Payments	fate_MilestonePayments	20,000,000.0
Milestone Payments	fate_MilestonePayments	30,000,000.0
Milestone Payments	fate_MilestonePayments	$ 25,000,000.0
Fair Value Assumptions Expected Volatility Rate1	fate_FairValueAssumptionsExpectedVolatilityRate1	78.30%
Fair Value Assumptions Expected Volatility Rate1	fate_FairValueAssumptionsExpectedVolatilityRate1	77.60%
C I R M Award Liability Current	fate_CIRMAwardLiabilityCurrent	$ 3,200,000
C I R M Award Liability Current	fate_CIRMAwardLiabilityCurrent	3,200,000
Collaborative Arrangement Aggregate Payments Receivable	fate_CollaborativeArrangementAggregatePaymentsReceivable	20,000,000.0
Collaborative Arrangement Aggregate Payments Receivable	fate_CollaborativeArrangementAggregatePaymentsReceivable	$ 29,300,000
Fair Value Assumptions Expected Term1	fate_FairValueAssumptionsExpectedTerm1	16 years 6 months
Fair Value Assumptions Expected Term1	fate_FairValueAssumptionsExpectedTerm1	17 years
Straight Line Lease Expense	fate_StraightLineLeaseExpense	$ 3,865,000
Straight Line Lease Expense	fate_StraightLineLeaseExpense	3,541,000
Straight Line Lease Expense	fate_StraightLineLeaseExpense	7,680,000
Straight Line Lease Expense	fate_StraightLineLeaseExpense	7,075,000
Collaborative Arrangements Upfront Payments Recorded Under Deferred Revenue	fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue	66,000,000.0
Collaborative Arrangements Upfront Payments Recorded Under Deferred Revenue	fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue	10,000,000.0
Collaborative Arrangements Upfront Payments Recorded Under Deferred Revenue	fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue	$ 10,000,000.0
Preferred Stock Conversion Price	fate_PreferredStockConversionPrice	$ 2.66
Regulatory And Sales Milestone Payment	fate_RegulatoryAndSalesMilestonePayment	$ 898,000,000.0
Regulatory And Sales Milestone Payment	fate_RegulatoryAndSalesMilestonePayment	$ 706,000,000.0
Share Price Fair Value Input	fate_SharePriceFairValueInput	$ 27.26
Share Price Fair Value Input	fate_SharePriceFairValueInput	$ 22.30
Increase Decrease In Fair Value Of Enterprise Value Milestones	fate_IncreaseDecreaseInFairValueOfEnterpriseValueMilestones	$ 5,900,000
Increase Decrease In Fair Value Of Enterprise Value Milestones	fate_IncreaseDecreaseInFairValueOfEnterpriseValueMilestones	14,200,000
Additional Candidate Milestone Payment	fate_AdditionalCandidateMilestonePayment	460,000,000.0
Additional Candidate Milestone Payment	fate_AdditionalCandidateMilestonePayment	340,000,000.0
Transaction Price Of Agreement	fate_TransactionPriceOfAgreement	66,000,000.0
Transaction Price Of Agreement	fate_TransactionPriceOfAgreement	39,300,000
Enterprise Value Milestones Liability At Fair Value	fate_EnterpriseValueMilestonesLiabilityAtFairValue	9,900,000
Short Term Investments And Related Maturity Receivables	fate_ShortTermInvestmentsAndRelatedMaturityReceivables	513,575,000
Short Term Investments And Related Maturity Receivables	fate_ShortTermInvestmentsAndRelatedMaturityReceivables	$ 482,327,000
Liquidity Policy [Text Block]	fate_LiquidityPolicyTextBlock	Going Concern Assessment Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.
Equity Premium	fate_EquityPremium	$ 16,000,000.0
Upfront Non Refundable And Non Creditable Payment	fate_UpfrontNonRefundableAndNonCreditablePayment	50,000,000.0
Upfront Non Refundable And Non Creditable Payment	fate_UpfrontNonRefundableAndNonCreditablePayment	$ 50,000,000.0
Warrants Exercise Terms Description	fate_WarrantsExerciseTermsDescription	The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company
Public Offering Of Common Stock And Issuance Of Pre Funded Warrants	fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	$ 5,000
Public Offering Of Common Stock And Issuance Of Pre Funded Warrants	fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	432,440,000
Public Offering Of Common Stock And Issuance Of Pre Funded Warrants	fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	432,445,000
Option Exercise Payment	fate_OptionExercisePayment	$ 10,000,000.0
Fair Value Assumptions Risk Free Interest Rate1	fate_FairValueAssumptionsRiskFreeInterestRate1	3.20%
Fair Value Assumptions Risk Free Interest Rate1	fate_FairValueAssumptionsRiskFreeInterestRate1	1.70%
Maximum Percentage Of Common Stock Ownership Together With Affiliates Allowable After Exercise Of Prefunded Warrants	fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants	9.99%
Cash Received Upon Achievement Of Each Milestone	fate_CashReceivedUponAchievementOfEachMilestone	$ 3,000,000.0
Stock Price Appreciation Milestone Payable	fate_StockPriceAppreciationMilestonePayable	$ 20,000,000.0
Maximum Percentage Of Common Stock Ownership After Change Upon Notice	fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice	19.99%
Collaborative Arrangement First Year Research And Development Fees Prepayment	fate_CollaborativeArrangementFirstYearResearchAndDevelopmentFeesPrepayment	$ 5,000,000.0
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	1,200,000
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	700,000
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	2,400,000
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	1,100,000
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	0
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	300,000
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	300,000
Amortization Of Sub License Consideration	fate_AmortizationOfSubLicenseConsideration	$ 500,000
Fair Value Inputs Stock Price Sensitivity Percentage Increase Decrease	fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease	10.00%
Fair Value Inputs Stock Price Sensitivity Percentage Increase Decrease	fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease	10.00%
Percentage Of Common Stock Ownership For Preferred Stock Conversion Change Upon Notice	fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice	19.99%
Short Term Investment Maturity Period Range Start	fate_ShortTermInvestmentMaturityPeriodRangeStart	3 months
Trailing Stock Price Per Share	fate_TrailingStockPricePerShare	$ 50.18
Trailing Stock Price Per Share	fate_TrailingStockPricePerShare	100.36
Trailing Stock Price Per Share	fate_TrailingStockPricePerShare	$ 150.54
Transfer of assets from level 1 to level 2	fate_TransferOfAssetsFromLevel1ToLevel2	$ 0
Percentage of Tax Credit	fate_PercentageOfTaxCredit	50.00%
Percentage of Tax Credit	fate_PercentageOfTaxCredit	70.00%
Accrued Clinical Trial Related Costs Current	fate_AccruedClinicalTrialRelatedCostsCurrent	$ 11,684,000
Accrued Clinical Trial Related Costs Current	fate_AccruedClinicalTrialRelatedCostsCurrent	$ 12,344,000
Collaborative Arrangement Percentage Of Reduction On Milestone Payments	fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments	50.00%
Short Term Investment Maturity Period Range End	fate_ShortTermInvestmentMaturityPeriodRangeEnd	36 months
Public Equity Offering Policy [Text Block]	fate_PublicEquityOfferingPolicyTextBlock	Public Equity Offerings In January 2021, the Company completed a public offering of common stock in which investors, certain of which are affiliated with a director of the Company, purchased 5.1 million shares of the Company’s common stock at a price of $85.50 per share under a shelf registration statement. In addition, the Company issued pre-funded warrants, in lieu of common stock to certain investors, to purchase 257,310 shares of the Company’s common stock (Pre-Funded Warrants). The purchase price of the Pre-Funded Warrants was $85.499 per Pre-Funded Warrant, which equals the per share public offering price for the shares of common stock less the $0.001 exercise price for each such Pre-Funded Warrant. See Note 8 for additional detail. Gross proceeds from the public offering and the issuance of the Pre-Funded Warrants were $460.0 million, and after giving effect to $27.6 million of costs related to the public offering and the issuance of Pre-Funded Warrants, net proceeds were $432.4 million.
Collaborative Arrangement Aggregate Milestone Payments Receivable	fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable	$ 843,000,000.0
C I R M Award Liability Noncurrent	fate_CIRMAwardLiabilityNoncurrent	800,000
C I R M Award Liability Noncurrent	fate_CIRMAwardLiabilityNoncurrent	800,000
Proceeds from Public Offering of Common Stock and Issuance of Pre-Funded Warrants	fate_ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	0
Proceeds from Public Offering of Common Stock and Issuance of Pre-Funded Warrants	fate_ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	432,446,000
Collaborative Arrangement Potential Additional Milestones	fate_CollaborativeArrangementPotentialAdditionalMilestones	9,300,000
Collaborative Arrangement Potential Additional Milestones	fate_CollaborativeArrangementPotentialAdditionalMilestones	29,300,000
Collaborative Arrangement Potential Additional Milestones	fate_CollaborativeArrangementPotentialAdditionalMilestones	20,000,000.0
Enterprise Value Milestone Payment	fate_EnterpriseValueMilestonePayment	$ 75,000,000.0
Purchase Price Of Prefunded Warrants	fate_PurchasePriceOfPrefundedWarrants	$ 85.499
Common Stock Of Public Offering And Issuance Of Pre Funded Warrants	fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants	5,122,807
Stock Price Appreciation Milestones	fate_StockPriceAppreciationMilestones	$ 9,928,000
Stock Price Appreciation Milestones	fate_StockPriceAppreciationMilestones	9,928,000
Stock Price Appreciation Milestones	fate_StockPriceAppreciationMilestones	24,168,000
Stock Price Appreciation Milestones	fate_StockPriceAppreciationMilestones	24,168,000
Increase Decrease In Right Of Use Assets And Lease Liabilities Net	fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	(287,000)
Increase Decrease In Right Of Use Assets And Lease Liabilities Net	fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	2,593,000
Fair Value Liabilities Level3 To Level2 Transfers Amount	fate_FairValueLiabilitiesLevel3ToLevel2TransfersAmount	0
Stock Price Appreciation Milestones Liabilities Non Current	fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent	9,928,000
Stock Price Appreciation Milestones Liabilities Non Current	fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent	$ 24,168,000
Common Stock Multiple	fate_CommonStockMultiple	5.0x
Common Stock Multiple	fate_CommonStockMultiple	10.0x
Common Stock Multiple	fate_CommonStockMultiple	15.0x
Convertible Preferred Stock Policy [Text Block]	fate_ConvertiblePreferredStockPolicyTextBlock	Convertible Preferred Stock The Company applies the relevant accounting standards to distinguish liabilities from equity when assessing the classification and measurement of preferred stock. Preferred shares subject to mandatory redemptions are considered liabilities and measured at fair value. Conditionally redeemable preferred shares are considered temporary equity. All other preferred shares are considered as stockholders’ equity. The Company applies the relevant accounting standards for derivatives and hedging (in addition to distinguishing liabilities from equity) when accounting for hybrid contracts that contain conversion options. Conversion options must be bifurcated from the host instruments and accounted for as free-standing financial instruments according to certain criteria. These criteria include circumstances when (i) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable accounting principles with changes in fair value reported in earnings as they occurred, and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently measured at fair value at each reporting date, with the changes in fair value reported in earnings.
Proceeds From Research And Development Fees Received	fate_ProceedsFromResearchAndDevelopmentFeesReceived	$ 49,400,000
Proceeds From Research And Development Fees Received	fate_ProceedsFromResearchAndDevelopmentFeesReceived	18,000,000.0
Fair Value Liabilities Level2 To Level3 Transfers Amount	fate_FairValueLiabilitiesLevel2ToLevel3TransfersAmount	0
Fair Value Liabilities Level3 To Level1 Transfers Amount	fate_FairValueLiabilitiesLevel3ToLevel1TransfersAmount	$ 0
Stock Price Appreciation Milestones Policy [Text Block]	fate_StockPriceAppreciationMilestonesPolicyTextBlock	Stock Price Appreciation Milestones The Company estimates the fair value of the stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (see Note 2), using a Monte Carlo simulation model, which relies on the Company’s current stock price as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. The Company accounts for the fair value of the stock price appreciation milestones in accordance with Accounting Standards Codification (ASC) 815, Derivatives and Hedging, with fair value marked-to-market at each reporting date. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the probability of achieving a specified clinical milestone, the expected volatility of the Company’s common stock, the risk-free interest rate, and the estimated term, which is based in part on the last valid patent claim date. The Company remeasures the fair value of the stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as non-operating income or expense on the unaudited condensed consolidated statements of operations and comprehensive loss.
Corresponding Asset For Sublicense Consideration Paid	fate_CorrespondingAssetForSublicenseConsiderationPaid	$ 4,000,000.0
Risks And Uncertainties Policy [Text Block]	fate_RisksAndUncertaintiesPolicyTextBlock	Risks and Uncertainties Due to the global outbreak of SARS-CoV-2, the strain of coronavirus that causes Coronavirus disease 2019 (COVID-19), the Company continued to experience impacts on certain aspects of its business, including its clinical trial, manufacturing, and research and development activities, during the six months ended June 30, 2022. For example, with the lifting of governmental stay-at-home orders, we have reopened each of our business locations for work onsite, but have also implemented flexible work arrangements in the interests of maintaining the health and safety of our employees. In addition, the COVID-19 pandemic has impacted the timing of our ongoing clinical studies, with slower site activation, patient enrollment and treatment in our clinical studies as a result of precautionary measures taken by some clinical trial sites to protect both site staff and patients from possible COVID-19 exposure. We have also experienced delays in obtaining equipment, materials, and supplies needed to maintain our operations and manufacture our product candidates as a result of production shortages experienced by our suppliers as a result of the COVID-19 pandemic. The scope and duration of these delays and disruptions, and the ultimate impacts of the ongoing COVID-19 pandemic on the Company’s operations, are currently unknown, and depend on continuously changing circumstances, including the emergence of new variants of the virus, such as the Omicron BA.4 and BA.5 variants. While certain measures have been relaxed in certain parts of the world as increasing numbers of people have received COVID-19 vaccines, others have remained in place with some areas continuing to experience renewed outbreaks and surges in infection rates. The extent to which such measures are removed or new measures are put in place will depend upon how the pandemic evolves, as well as the distribution of available vaccines, the rates at which they are administered and the emergence of new variants of the virus. The Company is continuing to actively monitor the situation and may take further precautionary and preemptive actions as may be required by federal, state or local authorities or that it determines are in the best interests of public health and safety and that of the Company’s patient community, employees, partners, and stockholders. The Company cannot predict the effects that such actions, or the impact of the ongoing COVID-19 pandemic on global business operations and economic conditions, may have on its business, strategy, collaborations, or financial and operating results.
Short Term Leases Term Excluded From Calculation Of Right Of Use Of Assets And Lease Liabilities	fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities	12 months
Fair Value Liabilities Level1 To Level3 Transfers Amount	fate_FairValueLiabilitiesLevel1ToLevel3TransfersAmount	$ 0
Transfer of assets from level 2 to level 1	fate_TransferOfAssetsFromLevel2ToLevel1	$ 0
Employee Retention Credit Policy	fate_EmployeeRetentionCreditPolicy	Employee Retention Credit The CARES Act provides an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes of up to $5,000 per employee for eligible employers. The tax credit is equal to 50% of qualified wages paid to employees during a quarter, capped at $10,000 of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $10,000 of qualified wages per quarter. The Company qualifies for the tax credit under the CARES Act and expects to continue to receive additional tax credits under the additional relief provisions for qualified wages through December 31, 2021. In connection with the CARES Act, the Company adopted a policy to recognize the employee retention credit when received and include in other income in the statement of operations. Accordingly, the Company received a cash payment and recorded $0.4 million of other income during the three and six months ended June 30, 2022.
Collaborative Arrangement Annual Payments Receivable Recorded Under Deferred Revenue	fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue	$ 5,000,000.0
Profit Loss Sharing Percentage	fate_ProfitLossSharingPercentage	50.00%
Refundable Tax Credit	fate_RefundableTaxCredit	$ 5,000
Stock Purchase Agreement [Member]
Stock Issued During Period Shares For Private Placement	fate_StockIssuedDuringPeriodSharesForPrivatePlacement	1,800,000
Aggregate Equity Premium On Shares Issued Under Agreement	fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement	$ 16,000,000.0
Equity Premium On Share Price Per Share Under Agreement	fate_EquityPremiumOnSharePricePerShareUnderAgreement	$ 9.93

California Institute For Regenerative Medicine Award (Details) $ in Millions		12 Months Ended
	Apr. 05, 2018 USD ($) Disbursement	Dec. 31, 2020
Award from California institute for regenerative medicine
Award agreement executed date	Apr. 05, 2018
Award for first-in-human clinical trial \| $	$ 4.0
Number of disbursements	5
Number of disbursement receivable upon the execution of the award	1
Number of disbursements receivable based on completion of certain operating milestones	4
Additional amount available for funding under award \| $	$ 4.0
Repayment percentage of award amount	100.00%
Period to treat award as grant, if award not treated as loan		10 years

Print Document View Excel Document
Notes to Financial Statements California Institute for Regenerative Medicine Award Notes Tables Collaboration and License Agreements (Tables) Notes Details California Institute For Regenerative Medicine Award (Details) Uncategorized Uncategorized Items - fate-20220630_htm.xml All Reports